NCT00298909

Brief Summary

The investigators want to study the relative effects of physical exercise vs. extended-release niacin (lipid-lowering drug) in patients with coronary heart disease and low HDL cholesterol ("good cholesterol") on

  • lipid profile
  • endothelial function as measured by ultrasound The endothelium is the inner part of the blood vessels. Impaired endothelial function is known to be associated with atherosclerosis which can ultimately lead to diseases such as stroke, heart attack and others. Endothelial function can be assessed non-invasively by ultrasound. Both interventions mentioned above have been shown to have a beneficial effect on lipid profile and endothelial function. However, the relative effects are unclear.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2006

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

March 2, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 3, 2006

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

July 31, 2012

Status Verified

July 1, 2012

Enrollment Period

3.3 years

First QC Date

March 2, 2006

Last Update Submit

July 29, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • relative effect on flow-mediated dilatation of radial artery

    6 months

Secondary Outcomes (5)

  • lipid profile

    6 months

  • biochemical markers of atherosclerosis

    6 months

  • expression of monocyte surface markers

    6 months

  • oxidative stress

    6 months

  • thrombogenicity

    6 months

Study Arms (3)

1

EXPERIMENTAL

niacin

Drug: niaspan (extended-release niacin)Drug: niacin

2

ACTIVE COMPARATOR

physical exercise

Behavioral: physical exercise

3

PLACEBO COMPARATOR

control

Other: control

Interventions

physical exercise

2

niaspan (extended-release niacin)

1
niacinDRUG

niacin extended-release

1
controlOTHER

control

3

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Coronary disease
  • Low HDL cholesterol
  • Age limits (see below)

You may not qualify if:

  • CAD with indication for bypass surgery
  • Left main disease ( \> 25% stenosis diameter)
  • Ejection fraction \< 40%
  • Higher degree heart valve disease
  • Higher degree ventricular arrhythmias
  • Type 1 Diabetes
  • Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)\> 5.0 mmol/L)
  • Severe liver disease
  • Thyroid disease
  • Alcohol or drug abuse
  • Pregnancy
  • Allergy against niacin oder other ingredient of niaspan
  • Acute gastric ulcer
  • Arterial bleeding
  • Uncontrolled severe arterial hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Leipzig Heart Center

Leipzig, 04289, Germany

Location

MeSH Terms

Conditions

Coronary DiseaseHypolipoproteinemias

Interventions

ExerciseNiacin

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesLipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaNicotinic AcidsAcids, HeterocyclicHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Steffen Desch, MD

    Heart Center Leipzig - University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Priv.-Doz. Dr. med.

Study Record Dates

First Submitted

March 2, 2006

First Posted

March 3, 2006

Study Start

March 1, 2006

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

July 31, 2012

Record last verified: 2012-07

Locations